{"id":30436,"date":"2020-11-11T18:40:29","date_gmt":"2020-11-11T18:40:29","guid":{"rendered":"https:\/\/amelie-project.eu\/?post_type=press-release&p=30436"},"modified":"2021-05-08T07:38:26","modified_gmt":"2021-05-08T07:38:26","slug":"a-ue-apoia-a-investigacao-pioneira-sobre-a-incontinencia-com-um-financiamento-de-9-5-milhoes-de-euros","status":"publish","type":"press-release","link":"https:\/\/amelie-project.eu\/pt\/comunicado-de-imprensa\/a-ue-apoia-a-investigacao-pioneira-sobre-a-incontinencia-com-um-financiamento-de-9-5-milhoes-de-euros\/","title":{"rendered":"A UE apoia a investiga\u00e7\u00e3o pioneira sobre a incontin\u00eancia com um financiamento de 9,5 milh\u00f5es de euros"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.6.3″ custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_row _builder_version=”4.6.3″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” width=”100%” module_alignment=”center” custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.6.3″ text_font=”Gotham kinda bold||||||||” text_text_color=”#000000″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false”]<\/p>\n

A UE concedeu 9,5 milh\u00f5es de euros a um projeto de investiga\u00e7\u00e3o inovador sobre o tratamento da incontin\u00eancia fecal.<\/p>\n

O objetivo da investiga\u00e7\u00e3o \u00e9 utilizar uma terapia celular revolucion\u00e1ria para encontrar uma poss\u00edvel cura para uma doen\u00e7a que afecta cerca de 67 milh\u00f5es de pessoas na Europa.<\/p>\n

O financiamento ser\u00e1 atribu\u00eddo a um cons\u00f3rcio de 13 organiza\u00e7\u00f5es de nove pa\u00edses denominado AMELIE (Anchored Muscle cELls for IncontinencE).<\/p>\n

O projeto ser\u00e1 coordenado pela UCL e dirigido por Richard Day, Professor de Tecnologia de Medicina Regenerativa na UCL.<\/p>\n

Outros parceiros no Reino Unido incluem a Queen Mary University of London, o NHS Blood and Transplant e a associa\u00e7\u00e3o Bowel Research UK, que assumir\u00e1 a lideran\u00e7a no envolvimento dos doentes.<\/p>\n

A investiga\u00e7\u00e3o ser\u00e1 realizada ao longo de cinco anos, com institui\u00e7\u00f5es distintas no Reino Unido, Espanha e Portugal a assumirem o papel principal em cada nova fase.<\/p>\n

O projeto centrar-se-\u00e1 na recolha de c\u00e9lulas musculares do pr\u00f3prio doente, carregando-as em microtransportadores especialmente concebidos e implantando-as no m\u00fasculo danificado para promover a regenera\u00e7\u00e3o e restaurar a fun\u00e7\u00e3o normal.<\/p>\n

O Professor Day afirmou que esta terapia de medicina regenerativa oferece esperan\u00e7a a muitas pessoas cujas vidas s\u00e3o gravemente afectadas pela incontin\u00eancia:<\/p>\n

\u201cEstamos extremamente entusiasmados com a perspetiva do projeto AMELIE e com os potenciais benef\u00edcios que podem advir da nova abordagem terap\u00eautica que est\u00e1 a ser investigada.<\/p>\n

\u201cAguardamos com expetativa a oportunidade de trabalhar com o excecional cons\u00f3rcio de acad\u00e9micos, cl\u00ednicos, ind\u00fastria e parceiros de caridade de toda a Europa para desenvolver a nossa abordagem pioneira de medicina regenerativa para o tratamento desta doen\u00e7a debilitante.<\/p>\n

\u201cEsta ser\u00e1 uma abordagem radical e inovadora, nunca antes tentada a esta escala.\u201d<\/p>\n

Lesley Booth MBE, Diretora de Investiga\u00e7\u00e3o e PPI da Bowel Research UK, afirmou que, embora a doen\u00e7a seja extremamente comum, n\u00e3o \u00e9 muito falada.<\/p>\n

\u201cA realidade de viver com incontin\u00eancia fecal pode ser devastadora. \u00c9 definitivamente uma limita\u00e7\u00e3o de vida. E o facto de ser uma doen\u00e7a que as pessoas n\u00e3o discutem livremente s\u00f3 vem aumentar as dificuldades de levar uma vida normal\u201d, disse ela.<\/p>\n

\u201cEncontrar uma terapia que funcione n\u00e3o seria apenas um grande avan\u00e7o m\u00e9dico, seria uma mudan\u00e7a de vida para milh\u00f5es de pessoas.\u201d<\/p>\n

Este projeto recebeu financiamento do programa de investiga\u00e7\u00e3o e inova\u00e7\u00e3o Horizonte 2020 da Uni\u00e3o Europeia ao abrigo do acordo de subven\u00e7\u00e3o n.\u00ba 874807.<\/p>\n

\n

<\/p>\n

[\/et_pb_text][et_pb_image src=”https:\/\/amelie-project.eu\/wp-content\/uploads\/2021\/01\/Picture-1.png” title_text=”Picture 1″ _builder_version=”4.6.3″ _module_preset=”default”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"

The EU has awarded \u20ac9.5m to a ground breaking research project into the treatment of faecal incontinence. The aim of the research is to use revolutionary cell therapy to find a possible cure for a condition which affects an estimated 67 million people in Europe. The funding will go to a consortium of 13 organisations across nine countries called AMELIE (Anchored Muscle cELls for IncontinencE). The project will be co-ordinated by UCL and led by Richard Day, Professor of Regenerative Medicine Technology at UCL. Other partners in the UK include Queen Mary University of London, NHS Blood and Transplant and the charity Bowel Research UK, which will take the lead in patient involvement. The research will be conducted over five years, with separate institutions in the UK, Spain and Portugal taking the lead role at each new stage. The project will focus on taking the patient\u2019s own muscle cells, loading them onto specially designed microcarriers and implanting them into the damaged muscle to promote regeneration and restore normal function. Professor Day said that such regenerative medicine therapy offers hope to many people whose lives are severely impaired by incontinence: \u201cWe are tremendously excited by the prospect of the AMELIE project […]<\/p>","protected":false},"featured_media":31025,"template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"\n

The EU has awarded \u20ac9.5m to a ground breaking research project into the treatment of faecal incontinence.<\/p>\n\n\n\n

The aim of the research is to use revolutionary cell therapy to find a possible cure for a condition which affects an estimated 67 million people in Europe. <\/p>\n\n\n\n

The funding will go to a consortium of 13 organisations across nine countries called AMELIE (Anchored Muscle cELls for IncontinencE).<\/p>\n\n\n\n

The project will be co-ordinated by UCL and led by Richard Day, Professor of Regenerative Medicine Technology at UCL.<\/p>\n\n\n\n

Other partners in the UK include Queen Mary University of London, NHS Blood and Transplant and the charity Bowel Research UK, which will take the lead in patient involvement.<\/em><\/p>\n\n\n\n

The research will be conducted over five years, with separate institutions in the UK, Spain and Portugal taking the lead role at each new stage.<\/p>\n\n\n\n

The project will focus on taking the patient\u2019s own muscle cells, loading them onto specially designed microcarriers and implanting them into the damaged muscle to promote regeneration and restore normal function.<\/p>\n\n\n\n

Professor Day said that such regenerative medicine therapy offers hope to many people whose lives are severely impaired by incontinence:<\/p>\n\n\n\n

\u201cWe are tremendously excited by the prospect of the AMELIE project and the potential benefits that may arise from the new therapeutic approach being investigated.<\/p>\n\n\n\n

\u201cWe look forward to working with the exceptional consortium of academics, clinicians, industry and charity partners from across Europe to develop our pioneering regenerative medicine approach for treating this debilitating condition.<\/p>\n\n\n\n

\u201cThis will be a radical and innovative approach never before attempted at such a scale.\u201d<\/p>\n\n\n\n

Lesley Booth MBE, Director of Research and PPI at Bowel Research UK, said that, whilst the condition is extremely common, it is not much talked about.<\/p>\n\n\n\n

\u201cThe reality of living with faecal incontinence can be devastating. It is definitely life-limiting. And the fact that it\u2019s a condition which people don\u2019t discuss freely just adds to the difficulties of leading a normal life,\u201d she said.<\/p>\n\n\n\n

\u201cFinding a therapy which works would not just be a major medical breakthrough, it would be life-changing for millions.\u201d<\/p>\n\n\n\n

This project has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No 874807.<\/p>\n\n\n\n

Ends<\/strong><\/p>\n\n\n\n

NOTES TO EDITORS<\/strong><\/p>\n\n\n\n

AMELIE<\/strong> (Anchored Muscle cELls for IncontinencE consortium) is made up of the following: University College London, Instituto Superior Tecnico (Portugal), Queen Mary University of London, Medical University of Graz (Austria), Aarhus University Hospital (Denmark), Rouen University Hospital (France), University Hospital Erlangen (Germany), Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (Spain), NHS Blood and Transplant (UK), Polysciences Europe GmbH (Germany), Ttopstart (Netherlands), Bowel Research (UK), Consorzio per Valutazioni Biologiche e Farmacologiche (Italy).<\/p>\n\n\n\n

Horizon 2020<\/strong> is an EU funding programme for research and innovation. It is the biggest EU Research and Innovation programme ever with nearly \u20ac80 billion of funding available over 7 years (2014 to 2020) \u2013 in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. https:\/\/ec.europa.eu\/programmes\/horizon2020\/en\/what-horizon-2020<\/a><\/p>\n\n\n\n

This project has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No 874807.<\/p>\n\n\n\n

AMELIE contact:<\/strong><\/p>\n\n\n\n

Media contact:<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n","_et_gb_content_width":"","_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_links_to":"","_links_to_target":""},"categories":[51],"class_list":["post-30436","press-release","type-press-release","status-publish","has-post-thumbnail","hentry","category-press-release"],"_links":{"self":[{"href":"https:\/\/amelie-project.eu\/pt\/wp-json\/wp\/v2\/press-release\/30436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/amelie-project.eu\/pt\/wp-json\/wp\/v2\/press-release"}],"about":[{"href":"https:\/\/amelie-project.eu\/pt\/wp-json\/wp\/v2\/types\/press-release"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/amelie-project.eu\/pt\/wp-json\/wp\/v2\/media\/31025"}],"wp:attachment":[{"href":"https:\/\/amelie-project.eu\/pt\/wp-json\/wp\/v2\/media?parent=30436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/amelie-project.eu\/pt\/wp-json\/wp\/v2\/categories?post=30436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}